CBLN1 and myeloid sarcoma: Although in the aforementioned studies there is convincing evidence for Cer abnormalities in MS, it relies mainly on preclinical models and their translation into human clinical context, with clear identification of Cer related mechanisms of action and potentially relevant MS biomarkers, still remains a challenge20, 4–7.